Artificial Axon Labs developed a transformational biomimetic platform to discover medicines for neurodegenerative diseases
3D-printed Artificial Axons
Our Vision
Transforming the discovery of medicines for neurodegeneration for every patient by bringing together engineered biomaterials, 3D printing, and human cells.
Our Science
We developed a transformational biomimetic platform to discover medicines for neurodegenerative diseases.
Our novel approach is based on direct measurement of myelination, to discover first-in-class remyelinating drugs with an initial focus on Multiple Sclerosis (MS).
Our proprietary cutting-edge technology, developed by the company founders at MIT, combines 3D printing of axon mimics and patient-derived human cells.
-
Using light to 3D-print axons
We have pushed beyond today’s boundaries of 3D printing technologies, where we’ve tackled the unmet needs of making sub-micrometer features with our ultra-low stiffness, biocompatible materials, to create structures just like axons in the brain.
-
Direct 3D myelination readout
Artificial Axons is the only assay that provides direct quantification of myelination in a three-dimensional axon-like environment mimicking the human brain.
-
Human cell compatibility
Artificial Axons is the only assay compatible with human cells, which allows us to address human disease directly, instead of using animal cells that have proven over and over to be insufficient to deliver a drug that works in humans.
Educational video about Artificial Axons
Platform validation
Our platform has been validated at MIT with industry and academic collaborators.
Validation of Artificial Axons as a pro-myelinating drug screening platform.
Optimizing Artificial Axons as the platform to study human myelination.
3D printing based fabrication of Artificial Axons.
Application of Artificial Axons for modeling Leukodystrophies (ALD).
Artificial Axons in modeling myelin disorders in genetic variants of MS and Alzheimer’s disease.
Team
-
Anna Jagielska, PhD, MIT, Biomaterials, Neuroscience
Founder, CEO/President
-
Kavin Kowsari, PhD, MIT, Biomaterials, 3D printing
Founder, CTO
-
Krystyn J. Van Vliet, PhD, Koerner Professor of Materials Science & Engineering and Biological Engineering, MIT
Scientific Co-Founder
-
Nicholas X. Fang, PhD, Professor of Mechanical Engineering, MIT
Scientific Co-Founder
-
Anna Voronova, PhD
Strategic Advisor
-
Nicholas Terrett, PhD
Medicinal Chemistry
News
Our latest paper highlighting the Artificial Axons platform, in collaboration with Sanofi, is published!
Artificial Axon Labs was one of the 20 companies that pitched at @MassBio Align Summit with insights by @McKinsey, keynotes, panel discussions, and pitches from other innovative seed/series A biotech, #healthtech, and #medtech startups. Registration link: https://www.massbio.org/events/listing/massbio-align-summit/
Artificial Axon Labs advanced to the final round of the MassChallenge 2023 awards, competing for up to $1M in equity-free cash prizes.
Artificial Axon Labs presented at Seed Showcase, part of Biotech Showcase 2023, with an online presentation available for viewing January 18-19.
Artificial Axon Labs’ proposal, written alongside implementation partner, RedWire Space, was selected through multiple rounds of judging and made it to the finals of the International Space Station National Laboratory (ISSNL) Technology in Space MassChallenge Prize.
Artificial Axon Labs made it to the final round of the Orbital Reef Starter Innovation Challenge!
Artificial Axon Labs pitched at the @MassChallenge U.S. Early Stage Startup Showcase on September 21, competing for MassChallenge’s Community Choice Award – a $25k zero-equity cash prize. Registration link: https://cvent.me/rDPdaV
Artificial Axon Labs presented a poster at #MALSI2022!
